1. Glycoproteomics-based liquid biopsy: translational outlook for colorectal cancer clinical management in Southeast Asia
   Gaayathri Kumarasamy et al, 2023, Future Oncology CrossRef
2. Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
   Joanne Chiu et al, 2023, BMC Med CrossRef
3. Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?
   Mara S. Serafini et al, 2023, The Journal of Liquid Biopsy CrossRef
4. Understanding the Landscape of Clinically Available Molecular Testing
   Julia A. Elvin, 2024, Surgical Oncology Clinics of North America CrossRef
5. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay
   Tadayoshi Hashimoto et al, 2024, Int J Clin Oncol CrossRef
6. Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer
   Zachary Gottschalk et al, 2024, Curr Oncol Rep CrossRef
7. Use of ctDNA in early breast cancer: analytical validity and clinical potential
   François Panet et al, 2024, npj Breast Cancer CrossRef
8. A Concise Overview of Circulating Tumor DNA Detection for Solid Tumors
   Eric Goold et al, 2024, Advances in Molecular Pathology CrossRef
9. Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis
   Qingxin Zhou et al, 2024, Journal of the National Cancer Center CrossRef
10. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
    B. Martínez-Castedo et al, 2024, Annals of Oncology CrossRef
11. Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment
    Giovanni Crisafulli, 2025, Genes CrossRef